Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging

Table 4 Subgroup analysis

All patients before LT			Eligibility for LT, n (%)	Patients who received LT
HCC	Number of patients	Total tumor diameter mean ± SD (cm), range		Number of sessions of DEB-TACE until LT (mean)	Deaths < 30 d (n)	Deaths > 30 d (n)	Recurrence (n, %)
Bridging	135		89 (65.9)		8	14	5 (5.81)
Group 1	90	3.22 ± 0.90 (2-5)	55 (61.1)	1.74	5	8	1
Group 2	27	4.16 ± 0.64 (3.2-5.7)	19 (70.3)	1.63	3	2	1
Group 3	18	5.70 ± 0.81 (4.7-7.5)	15 (83.3)	1.6	0	4	3
Downstaging	62		21 (33.9)		0	3	5 (25)
Group 1	11	6.52 ± 0.70 (5.7-8)	3 (27.3)	1.33	0	0	0
Group 2	19	6.53 ± 0.95 (4.6-7.9)	11 (57.9)	1.54	0	2	3
Group 3	5	6.56 ± 0.56 (5.9-7.2)	2 (40)	2.5	0	1	1
Group 4	5	7.2 ± 0.34 (6.9-7.7)	3 (60)	3	0	0	0
Group 5	22	10.92 ± 2.92 (8.2-17.2)	2 (9.1)	4	0	0	1

Cause of deaths: Bridging < 30 d: 3 Severe graft disfunction; 2 Sepsis; 2 Hemorrhagic shock; 1 Cardiogenic shock. Downstaging < 30 d: 0. Bridging > 30 d: 5 Sepsis; 4 Hepatocellular carcinoma recurrence; 1 Graft rejection; 1 Severe graft disfunction; 1 Pulmonary metastasis; 1 Stroke after brain biopsy; 1 not found. Downstaging > 30 d: 2 Hepatocellular carcinoma recurrence; 1 Pulmonary metastasis. HCC: Hepatocellular carcinoma; LT: Liver transplant.